The global thoracic aortic aneurysm market is forecasted to grow from USD 1.9 billion in 2025 to approximately USD 6.6 billion by 2035, recording an absolute increase of USD 4.73 billion over the forecast period. This translates into a total growth of 252.9%, with the market forecast to expand at a CAGR of 13.4% between 2025 and 2035. The market size is expected to grow by nearly 3.53X during the same period, supported by increasing prevalence of thoracic aortic aneurysms, advancing endovascular technologies, rising geriatric population, and growing awareness about minimally invasive treatment options.
Between 2025 and 2030, the thoracic aortic aneurysm market is projected to expand from USD 1.9 billion to USD 3.4 billion, resulting in a value increase of USD 1.53 billion, which represents 32.3% of the total forecast growth for the decade. This phase of growth will be shaped by increasing adoption of endovascular procedures, technological advancements in stent graft designs, expanding healthcare infrastructure in emerging markets, and growing physician training programs for complex aortic interventions. Medical device manufacturers are expanding their thoracic aortic repair product portfolios to address the growing demand for minimally invasive treatment solutions.
| Metric | Value |
|---|---|
| Estimated Value in (2025E) | USD 1.87 billion |
| Forecast Value in (2035F) | USD 6.6 billion |
| Forecast CAGR (2025 to 2035) | 13.4% |
From 2030 to 2035, the market is forecast to grow from USD 3.4 billion to USD 6.6 billion, adding another USD 3.2 billion, which constitutes 67.7% of the ten-year expansion. This period is expected to be characterized by widespread adoption of next-generation endovascular devices, integration of artificial intelligence in surgical planning, development of patient-specific treatment approaches, and expansion of complex aortic repair centers globally. The growing adoption of hybrid procedures and fenestrated/branched endovascular techniques will drive demand for advanced thoracic aortic repair solutions with enhanced safety and efficacy profiles.
Between 2020 and 2025, the thoracic aortic aneurysm market experienced significant expansion, driven by increasing prevalence of aortic diseases, aging population demographics, and technological innovations in endovascular repair techniques. The market developed as medical device companies recognized the need for less invasive treatment options compared to traditional open surgical approaches. Clinical evidence supporting the safety and efficacy of TEVAR procedures began establishing endovascular repair as the preferred treatment modality for suitable thoracic aortic aneurysm patients.
Market expansion is being supported by the increasing prevalence of thoracic aortic aneurysms driven by aging populations, lifestyle-related risk factors, and improved diagnostic capabilities that enable earlier detection of asymptomatic cases. Modern healthcare systems are increasingly focused on minimally invasive treatment approaches that can reduce patient morbidity, shorten recovery times, and decrease healthcare costs. TEVAR's proven efficacy in treating thoracic aortic aneurysms with reduced procedural risks compared to open surgery makes it a preferred treatment option in appropriate patient populations.
The growing focus on advanced medical technologies and precision medicine is driving demand for next-generation endovascular devices with improved deliverability, durability, and anatomical compatibility. Healthcare provider preference for procedures that offer better patient outcomes while reducing hospital stays is creating opportunities for innovative device designs and treatment approaches. The rising influence of clinical guidelines and evidence-based medicine is also contributing to increased adoption of endovascular repair techniques across different patient demographics and anatomical complexities.
The market is segmented by treatment outlook, product outlook, end use outlook, and region. By treatment outlook, the market is divided into thoracic endovascular aneurysm repair (TEVAR), open surgical repair (OSR), branched endovascular aneurysm repair (BEVAR), and hybrid procedures. Based on product outlook, the market is categorized into aortic stent grafts, aortic surgical grafts, and aortic repair accessory devices. In terms of end use outlook, the market is segmented into hospitals, ambulatory surgery centers (ASC), and clinics. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The Thoracic Endovascular Aneurysm Repair (TEVAR) treatment is projected to account for 64.2% of the thoracic aortic aneurysm market in 2025, reaffirming its position as the preferred minimally invasive treatment modality. Healthcare providers and patients increasingly recognize the advantages of endovascular repair over traditional open surgical approaches, including reduced procedural risk, shorter recovery times, and improved patient outcomes in appropriate anatomical cases. TEVAR's well-documented clinical benefits directly address the need for effective treatment while minimizing surgical trauma and complications.
This treatment approach forms the foundation of most modern aortic intervention strategies, as it represents the most advanced and patient-friendly therapeutic option for suitable thoracic aortic aneurysms. Physician training programs and ongoing technological innovations continue to expand the applicability of TEVAR procedures. With growing evidence supporting long-term durability and safety, endovascular repair aligns with both patient preferences and healthcare system goals for efficient, effective treatment delivery across diverse patient populations.
Aortic stent grafts are projected to represent 79% of thoracic aortic aneurysm product demand in 2025, underscoring their role as the essential device technology for endovascular aortic repair procedures. Healthcare providers rely on stent grafts for their ability to exclude aneurysmal segments while maintaining aortic blood flow, providing durable repair solutions through minimally invasive delivery systems. Positioned as the cornerstone technology for TEVAR procedures, stent grafts offer both immediate aneurysm exclusion and long-term protection against rupture risk.
The segment is supported by continuous technological advancement in graft materials, delivery systems, and device design optimization for complex anatomical scenarios. Manufacturers are increasingly developing specialized stent grafts for specific aortic zones, branched configurations, and challenging anatomical variants, enhancing procedural success rates and expanding treatment eligibility. As clinical evidence continues to support excellent long-term outcomes, aortic stent grafts will maintain their dominant market position, reinforcing their critical role within the thoracic aortic repair ecosystem.
The hospitals segment is forecasted to contribute 77% of the thoracic aortic aneurysm market in 2025, reflecting the complex nature of aortic interventions and the specialized infrastructure requirements for thoracic aortic repair procedures. Hospitals provide the comprehensive cardiovascular surgery capabilities, advanced imaging technologies, and multidisciplinary team expertise necessary for successful thoracic aortic aneurysm treatment. This setting ensures access to emergency surgical backup, intensive care support, and specialized nursing care critical for optimal patient outcomes.
The hospital environment supports both elective and emergency aortic interventions, providing the full spectrum of treatment modalities from endovascular repair to open surgical approaches. The segment benefits from established referral networks, specialized aortic centers of excellence, and comprehensive cardiac surgery programs that ensure appropriate patient selection and procedural expertise. With the increasing complexity of thoracic aortic cases and the need for multidisciplinary care coordination, hospitals serve as the primary treatment setting, making them the dominant end-use segment driving market demand and technological adoption.
The thoracic aortic aneurysm market is advancing rapidly due to increasing disease prevalence, technological innovations in endovascular devices, and growing physician expertise in minimally invasive repair techniques. The market faces challenges including complex anatomical variations, device-related complications, high procedural costs, and limited availability of specialized treatment centers in emerging markets. Innovation in device design, imaging guidance systems, and surgical training programs continue to influence treatment adoption and market expansion patterns.
The continuous development of next-generation stent graft technologies is enabling treatment of increasingly complex thoracic aortic pathologies with improved safety and efficacy profiles. Advanced imaging modalities including 3D reconstruction, fusion imaging, and real-time guidance systems are enhancing procedural precision and reducing complications. These technological improvements expand the pool of patients eligible for minimally invasive treatment while improving long-term durability outcomes.
Modern thoracic aortic aneurysm management is incorporating artificial intelligence for treatment planning, risk stratification, and outcome prediction to optimize patient selection and procedural success rates. AI-powered imaging analysis and predictive modeling are enabling personalized treatment approaches that consider individual anatomical characteristics and risk factors. These advanced technologies improve decision-making processes while supporting the development of patient-specific treatment protocols that enhance care quality.
| Country | CAGR (2025-2035) |
|---|---|
| China | 18% |
| India | 16.7% |
| Germany | 15.4% |
| France | 14% |
| UK | 12.7% |
| USA | 11.4% |
| Brazil | 10% |
The thoracic aortic aneurysm market is experiencing robust growth globally, with China leading at an 18.0% CAGR through 2035, driven by rapidly aging population, expanding healthcare infrastructure, and increasing adoption of advanced endovascular technologies. India follows at 16.7%, supported by growing cardiovascular disease burden, improving healthcare access, and rising medical device market penetration. Germany shows strong growth at 15.4%, emphasizing advanced surgical techniques and comprehensive aortic treatment programs. France records 14.0%, focusing on clinical innovation and specialized cardiovascular care delivery. The UK demonstrates 12.7% growth, prioritizing evidence-based treatment protocols and cost-effective healthcare solutions. The report covers an in-depth analysis of 40+ countries; top-performing countries are highlighted below.
Revenue from thoracic aortic aneurysm treatments in China is projected to exhibit strong growth with a CAGR of 18% through 2035, driven by rapid expansion of cardiovascular surgery capabilities and increasing adoption of minimally invasive treatment techniques among the aging population. The country's growing healthcare investment and development of specialized aortic treatment centers are creating significant demand for advanced endovascular devices and surgical expertise. Major international and domestic medical device manufacturers are establishing comprehensive distribution networks to serve the expanding population of thoracic aortic aneurysm patients across tier-1 and tier-2 cities.
Revenue from thoracic aortic aneurysm treatments in India is expanding at a CAGR of 16.7%, supported by increasing cardiovascular disease prevalence, growing healthcare infrastructure, and rising adoption of advanced medical technologies. The country's expanding medical tourism sector and increasing healthcare investments are driving demand for specialized aortic treatment capabilities and advanced endovascular devices. International medical device companies and healthcare providers are establishing treatment centers to serve the growing demand for cardiovascular interventions.
Demand for thoracic aortic aneurysm treatments in the USA is projected to grow at a CAGR of 11.4%, supported by advanced healthcare infrastructure, established aortic surgery programs, and focus on value-based cardiovascular care delivery. American healthcare systems are increasingly focused on evidence-based treatment protocols, cost-effective interventions, and improved patient outcomes through specialized aortic centers of excellence. The market is characterized by strong demand for next-generation endovascular devices that combine safety, efficacy, and long-term durability.
Revenue from thoracic aortic aneurysm treatments in Germany is projected to grow at a CAGR of 15.4% through 2035, driven by the country's strong cardiovascular surgery heritage, comprehensive healthcare system, and commitment to medical innovation. German healthcare providers consistently demand high-quality, clinically proven treatment solutions that deliver superior patient outcomes while maintaining cost-effectiveness within the healthcare system.
Revenue from thoracic aortic aneurysm treatments in the UK is projected to grow at a CAGR of 12.7% through 2035, supported by National Health Service commitment to evidence-based cardiovascular care and established aortic surgery expertise across specialized treatment centers. British healthcare providers value clinical evidence, cost-effectiveness, and proven long-term outcomes, positioning advanced endovascular repair as a core component of thoracic aortic aneurysm treatment protocols.
Revenue from thoracic aortic aneurysm treatments in France is projected to grow at a CAGR of 14.0% through 2035, supported by the country's strong cardiovascular surgery tradition, advanced medical education system, and commitment to clinical innovation. French healthcare providers prioritize surgical excellence, advanced techniques, and comprehensive patient care, making sophisticated aortic repair procedures a trusted choice in the cardiovascular intervention segment.
The thoracic aortic aneurysm market is characterized by competition among established medical device manufacturers, specialized cardiovascular companies, and emerging endovascular technology developers. Companies are investing in advanced device technologies, clinical research programs, physician training initiatives, and global market expansion strategies to deliver safe, effective, and accessible thoracic aortic repair solutions. Product innovation, clinical evidence generation, and healthcare provider relationships are central to strengthening market position and treatment adoption.
Medtronic , USA-based, leads the market with 34.0% global value share, offering comprehensive thoracic endovascular repair systems with focus on device reliability and clinical outcomes. W.L. Gore & Associates, Inc., USA, provides advanced endovascular grafts with focus on material innovation and long-term durability. Cook Medical, USA, delivers specialized aortic repair devices with focus on complex anatomical solutions and physician support. Terumo Corporation, Japan, focuses on minimally invasive technologies that combine endovascular expertise with advanced delivery systems.
MicroPort and Boston Scientific Corporation provide comprehensive endovascular product portfolios across multiple device categories and global markets. Artivion Inc., USA, emphasizes surgical grafts and tissue-based solutions with premium positioning. Cardiatis S.A., Belgium, offers specialized branched and fenestrated devices for complex aortic repair procedures. Endologix Inc., Braile Biomédica, and Lombard Medical provide innovative endovascular solutions with focus on specific anatomical challenges and emerging market opportunities.
| Items | Values |
|---|---|
| Quantitative Units (2025) | USD 1.87 billion |
| Treatment Outlook | Thoracic Endovascular Aneurysm Repair (TEVAR), Open Surgical Repair (OSR), Branched Endovascular Aneurysm Repair (BEVAR), Hybrid Procedures |
| Product Outlook | Aortic Stent Grafts, Aortic Surgical Grafts, Aortic Repair Accessory Devices |
| End Use Outlook | Hospitals, Ambulatory Surgery Centers (ASC), Clinics |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Countries Covered | United States, Canada, United Kingdom, Germany, France, China, Japan, South Korea, India, Brazil, Australia and 40+ countries |
| Key Companies Profiled | Medtronic, W.L. Gore & Associates, Inc., Cook Medical, Terumo Corporation, MicroPort, Boston Scientific Corporation, Artivion Inc., Cardiatis S.A., Endologix Inc., Braile Biomédica, and Lombard Medical |
| Additional Attributes | Dollar sales by device type and anatomical configuration, regional demand trends, competitive landscape, healthcare provider preferences for endovascular versus surgical approaches, integration with minimally invasive positioning, innovations in device design, delivery systems, and clinical outcome optimization |
The global thoracic aortic aneurysm market is estimated to be valued at USD 1.9 billion in 2025.
The market size for the thoracic aortic aneurysm market is projected to reach USD 6.6 billion by 2035.
The thoracic aortic aneurysm market is expected to grow at a 13.4% CAGR between 2025 and 2035.
The key product types in thoracic aortic aneurysm market are thoracic endovascular aneurysm repair (tevar), open surgical repair (osr), branched endovascular aneurysm repair (bevar) and hybrid procedures.
In terms of product outlook, aortic stent grafts segment to command 79.0% share in the thoracic aortic aneurysm market in 2025.
Explore Similar Insights
Thoracic Aortic Aneurysm Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
